Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity.
DNA methylation
Gene expression
Genomics
Immune profiling
Lung cancer
Metastasis
Multiomics
Journal
Genome biology
ISSN: 1474-760X
Titre abrégé: Genome Biol
Pays: England
ID NLM: 100960660
Informations de publication
Date de publication:
04 11 2020
04 11 2020
Historique:
received:
06
05
2020
accepted:
05
10
2020
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
1
12
2021
Statut:
epublish
Résumé
Metastasis is the primary cause of cancer mortality accounting for 90% of cancer deaths. Our understanding of the molecular mechanisms driving metastasis is rudimentary. We perform whole exome sequencing (WES), RNA sequencing, methylation microarray, and immunohistochemistry (IHC) on 8 pairs of non-small cell lung cancer (NSCLC) primary tumors and matched distant metastases. Furthermore, we analyze published WES data from 35 primary NSCLC and metastasis pairs, and transcriptomic data from 4 autopsy cases with metastatic NSCLC and one metastatic lung cancer mouse model. The majority of somatic mutations are shared between primary tumors and paired distant metastases although mutational signatures suggest different mutagenesis processes in play before and after metastatic spread. Subclonal analysis reveals evidence of monoclonal seeding in 41 of 42 patients. Pathway analysis of transcriptomic data reveals that downregulated pathways in metastases are mainly immune-related. Further deconvolution analysis reveals significantly lower infiltration of various immune cell types in metastases with the exception of CD4+ T cells and M2 macrophages. These results are in line with lower densities of immune cells and higher CD4/CD8 ratios in metastases shown by IHC. Analysis of transcriptomic data from autopsy cases and animal models confirms that immunosuppression is also present in extracranial metastases. Significantly higher somatic copy number aberration and allelic imbalance burdens are identified in metastases. Metastasis is a molecularly late event, and immunosuppression driven by different molecular events, including somatic copy number aberration, may be a common characteristic of tumors with metastatic plasticity.
Sections du résumé
BACKGROUND
Metastasis is the primary cause of cancer mortality accounting for 90% of cancer deaths. Our understanding of the molecular mechanisms driving metastasis is rudimentary.
RESULTS
We perform whole exome sequencing (WES), RNA sequencing, methylation microarray, and immunohistochemistry (IHC) on 8 pairs of non-small cell lung cancer (NSCLC) primary tumors and matched distant metastases. Furthermore, we analyze published WES data from 35 primary NSCLC and metastasis pairs, and transcriptomic data from 4 autopsy cases with metastatic NSCLC and one metastatic lung cancer mouse model. The majority of somatic mutations are shared between primary tumors and paired distant metastases although mutational signatures suggest different mutagenesis processes in play before and after metastatic spread. Subclonal analysis reveals evidence of monoclonal seeding in 41 of 42 patients. Pathway analysis of transcriptomic data reveals that downregulated pathways in metastases are mainly immune-related. Further deconvolution analysis reveals significantly lower infiltration of various immune cell types in metastases with the exception of CD4+ T cells and M2 macrophages. These results are in line with lower densities of immune cells and higher CD4/CD8 ratios in metastases shown by IHC. Analysis of transcriptomic data from autopsy cases and animal models confirms that immunosuppression is also present in extracranial metastases. Significantly higher somatic copy number aberration and allelic imbalance burdens are identified in metastases.
CONCLUSIONS
Metastasis is a molecularly late event, and immunosuppression driven by different molecular events, including somatic copy number aberration, may be a common characteristic of tumors with metastatic plasticity.
Identifiants
pubmed: 33148332
doi: 10.1186/s13059-020-02175-0
pii: 10.1186/s13059-020-02175-0
pmc: PMC7640699
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
271Subventions
Organisme : Wellcome Trust
ID : 211179/Z/18/Z
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Références
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Science. 1976 Oct 1;194(4260):23-8
pubmed: 959840
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Genome Biol. 2016 Feb 22;17:31
pubmed: 26899170
J Mol Diagn. 2015 Jan;17(1):53-63
pubmed: 25468433
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Ann Oncol. 2015 Jan;26(1):64-70
pubmed: 25319062
Cancer Discov. 2017 Oct;7(10):1088-1097
pubmed: 28733428
Br J Cancer. 1980 Sep;42(3):462-72
pubmed: 7426348
Nat Genet. 2015 Mar;47(3):209-16
pubmed: 25665006
Nat Commun. 2020 Jan 30;11(1):603
pubmed: 32001676
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
J Thorac Oncol. 2018 Jun;13(6):779-791
pubmed: 29526824
Nat Rev Genet. 2012 Nov;13(11):795-806
pubmed: 23044827
Eur J Cancer. 2006 Apr;42(6):717-27
pubmed: 16520032
Cancer Discov. 2015 Nov;5(11):1164-1177
pubmed: 26410082
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
FEBS Open Bio. 2018 Aug 30;8(9):1544-1552
pubmed: 30186753
Nature. 2017 Aug 17;548(7667):297-303
pubmed: 28783718
Nat Commun. 2014 Oct 28;5:5241
pubmed: 25348003
PLoS One. 2009;4(4):e5401
pubmed: 19404390
Cell Rep. 2013 Jan 31;3(1):246-59
pubmed: 23318258
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Lung Cancer. 2018 Jul;121:54-60
pubmed: 29858028
BMC Genomics. 2014 Dec 08;15:1079
pubmed: 25486910
Ann Oncol. 2017 Sep 1;28(9):2135-2141
pubmed: 28911083
Nature. 2015 Apr 16;520(7547):353-357
pubmed: 25830880
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
Cancer Discov. 2019 May;9(5):628-645
pubmed: 30787016
Nat Rev Immunol. 2003 Jan;3(1):23-35
pubmed: 12511873
Nat Methods. 2014 Apr;11(4):396-8
pubmed: 24633410
J Natl Cancer Inst. 1984 Dec;73(6):1319-26
pubmed: 6096621
BMC Cancer. 2019 Jan 7;19(1):19
pubmed: 30616523
Cell Rep. 2019 Feb 5;26(6):1518-1532.e9
pubmed: 30726735
Cell. 2011 Oct 14;147(2):275-92
pubmed: 22000009
Curr Top Microbiol Immunol. 2006;305:25-50
pubmed: 16724799
Cancer Discov. 2015 Jun;5(6):610-21
pubmed: 25929848
Int J Cancer. 1988 Jun 15;41(6):855-8
pubmed: 3372061
Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2):
pubmed: 29610390
N Engl J Med. 2016 Dec 8;375(23):2255-2262
pubmed: 27959684
Nat Commun. 2019 Jul 5;10(1):2978
pubmed: 31278276
Mod Pathol. 2018 Jun;31(6):947-955
pubmed: 29410488
Oncotarget. 2017 Mar 28;8(13):21994-22002
pubmed: 28423542
Genome Res. 2013 Jan;23(1):152-8
pubmed: 23028187
Science. 2017 Oct 13;358(6360):234-238
pubmed: 28912133
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Science. 1977 Aug 26;197(4306):893-5
pubmed: 887927
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
J Thorac Oncol. 2018 Oct;13(10):1496-1507
pubmed: 29933065
Lancet. 1996 May 18;347(9012):1377-81
pubmed: 8637346
Front Oncol. 2019 Jul 30;9:676
pubmed: 31417865
J Thorac Dis. 2018 Apr;10(Suppl 7):S876-S881
pubmed: 29780634
Bioinformatics. 2009 Nov 1;25(21):2865-71
pubmed: 19561018
Nat Methods. 2016 Sep 29;13(10):806-7
pubmed: 27684579
Science. 2016 Apr 8;352(6282):169-75
pubmed: 27124450
Trends Immunol. 2007 Jan;28(1):12-8
pubmed: 17129764
Bioinformatics. 2016 Oct 1;32(19):3015-7
pubmed: 27288500
Sci Transl Med. 2017 Mar 1;9(379):
pubmed: 28251903
Curr Opin Pharmacol. 2008 Aug;8(4):496-507
pubmed: 18691672
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Genome Biol. 2016 Aug 22;17(1):174
pubmed: 27549193
Nat Genet. 2017 Apr;49(4):594-599
pubmed: 28263318
Cancer Discov. 2018 Sep;8(9):1156-1175
pubmed: 30012853
Ann Oncol. 2019 Sep 1;30(9):1521-1530
pubmed: 31282941
Nat Commun. 2013;4:2612
pubmed: 24113773
Gastroenterology. 2019 Dec;157(6):1630-1645.e6
pubmed: 31560893
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Science. 1982 Sep 10;217(4564):998-1003
pubmed: 7112116
Nature. 1980 Jan 10;283(5743):139-46
pubmed: 6985715